A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery (NCT06497699) | Clinical Trial Compass
CompletedPhase 4
A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery
China263 participantsStarted 2021-10-28
Plain-language summary
This is a prospective, real-world study aimed to evaluate the efficacy and safety of Dexycu in treating postoperative inflammation of cataracts.
Who can participate
Age range40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subjects must be able to understand and sign the informed consent form and be able to follow the study procedures.
* Male or female subjects over 40 years of age who are scheduled to undergo cataract phacoemulsification surgery combined with intraocular lens implantation.
Exclusion Criteria:
* Known hypersensitivity to dexamethasone or any component of the Dexycu.
* History of intraocular inflammation of any cause in either eye, presence of corneal abnormalities or malnutrition.
* Have high intraocular pressure, with an IOP(intraocular pressure) of \> 21 mmHg in the test eye at screening, regardless of whether receiving anti-glaucoma monotherapy therapy.
* Posterior capsule rupture or lens dislocation, anterior vitreal membrane rupture, vitreous prolapse and intraoperative floppy iris syndrome during cataract surgery.
* Other conditions that the investigator considers inappropriate to participate the study.